4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Mantle Cell Lymphoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1191 ongoing clinical trials involving Mantle Cell Lymphoma
Of the 1191 trials,331 trials are in Phase II
Furthermore, 317 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Mantle Cell Lymphoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Mantle Cell Lymphoma, an Oncology condition. The largest number of ongoing clinical trials for Mantle Cell Lymphoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Mantle Cell Lymphoma-related drug trials.

University of Texas MD Anderson Cancer Center: The leading ongoing Mantle Cell Lymphoma related clinical trial sponsor

University of Texas MD Anderson Cancer Center is the top sponsor for Mantle Cell Lymphoma-related ongoing clinical trials.

City of Hope, Memorial Sloan Kettering Cancer Center, Masonic Cancer Center, University of Minnesota, and BeiGene Ltd are among other notable clinical trial sponsors involved in Mantle Cell Lymphoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Mantle Cell Lymphoma

Lenalidomide (Revlimid), Rituximab (MabThera, Rituxan, Ristova), and Ibrutinib (Imbruvica) are among the key marketed drugs involving Mantle Cell Lymphoma.

Lenalidomide (Revlimid) is a thalidomide analogue and an immunomodulatory imide drug (IMiD). It functions via the Protein cereblon (CRBN) Activator mechanism of action. It is formulated as hard gelatin capsules for the oral route of administration. Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM), as maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplantation (auto-HSCT). Lenalidomide was first approved in 2005 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Celgene Corp.

Rituximab (MabThera, Rituxan, Ristova) is an anti-neoplastic agent. It functions via Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20 mechanism of action. It is formulated as an injectable concentrate for solution for intravenous route and solution for the subcutaneous route of administration. Rituximab intravenous formulation is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. Rituximab was first approved in 1997 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Genentech USA Inc.